Area of research
Immunology · Oncology
Research interest
Research interests include Immune Cell Function and Interaction, T-cell and B-cell Immunology, Immunotherapy and Immune Responses, and CAR-T cell therapy research.
Supplementary Figures from Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
Supplementary Tables from Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
Supplementary Materials and methods from Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
Data from Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity.
CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms.
Author Correction: IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity.
Supplementary Materials and methods from Pre-existing immunity drives the response to neoadjuvant chemotherapy in esophageal adenocarcinoma
Supplementary Tables from Pre-existing immunity drives the response to neoadjuvant chemotherapy in esophageal adenocarcinoma
Supplementary Figures from Pre-existing immunity drives the response to neoadjuvant chemotherapy in esophageal adenocarcinoma
Supplementary Tables from Pre-existing immunity drives the response to neoadjuvant chemotherapy in esophageal adenocarcinoma
Supplementary Materials and methods from Pre-existing immunity drives the response to neoadjuvant chemotherapy in esophageal adenocarcinoma
Supplementary Figures from Pre-existing immunity drives the response to neoadjuvant chemotherapy in esophageal adenocarcinoma
Data from Pre-existing immunity drives the response to neoadjuvant chemotherapy in esophageal adenocarcinoma
Fasting mimicking diet in mice delays cancer growth and reduces immunotherapy-associated cardiovascular and systemic side effects.
Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma.
Supplementary Figures from Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
Supplementary Tables from Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
Data from Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
Supplementary Materials and methods from Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
Supplementary Tables from Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
Supplementary Materials and methods from Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
Supplementary Figures from Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells.
Exploiting CD1-restricted T cells for clinical benefit.
Flow cytometry data mining by cytoChain identifies determinants of exhaustion and stemness in TCR-engineered T cells.
Cytokine-Induced Memory-Like NK Cells with High Reactivity against Acute Leukemia Blasts and Solid Tumor Cells Suitable for Adoptive Immunotherapy Approaches.
Exploiting B-cell Receptor Stereotypy to Design Tailored Immunotherapy in Chronic Lymphocytic Leukemia.
Human T cells engineered with a leukemia lipid-specific TCR enables donor-unrestricted recognition of CD1c-expressing leukemia.
Editorial: NKT Cells in Cancer Immunotherapy.